In Vitro In Vivo [1]
NICE has approved semaglutide 2.4 mg (Wegovy) for use within specialist weight management services (NICE TA875), subject to specific eligibility criteria including a BMI of 35 kg/m or above (or 32.5 kg/m or above in people from certain ethnic minority backgrounds at higher metabolic risk) alongside at least one weight-related comorbidity
Essentially, natural GLP1 helps the body regulate blood sugar levels and control appetite
We serve patients from Hopewell Junction NY, Stormville NY, Beekman NY, Wappingers Falls NY, Kent NY, Pawling NY, and surrounding areas
However, because the gastric bypass creates a smaller stomach pouch and reroutes the digestive tract, it may result in slightly greater restriction in food intake compared to gastric sleeve
Its the first-ever drug that's a dual GIP and GLP-1 receptor agonist